###begin article-title 0
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 57 62 <span type="species:ncbi:9606">Human</span>
Anti-EGFR Antibody Efficiently and Specifically Inhibits Human TSC2-/- Smooth Muscle Cell Proliferation. Possible Treatment Options for TSC and LAM
###end article-title 0
###begin p 1
Conceived and designed the experiments: EL AG. Performed the experiments: EL VG SA. Analyzed the data: EL VG AG. Contributed reagents/materials/analysis tools: SC. Wrote the paper: EL AG. Discussed the research project: AMDG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC1</italic>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 269 272 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 436 439 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 203 210 <span type="species:ncbi:9606">patient</span>
 Tuberous sclerosis complex (TSC), a tumor syndrome caused by mutations in TSC1 or TSC2 genes, is characterized by the development of hamartomas. We previously isolated, from an angiomyolipoma of a TSC2 patient, a homogenous population of smooth muscle-like cells (TSC2-/- ASM cells) that have a mutation in the TSC2 gene as well as TSC2 loss of heterozygosity (LOH) and consequently, do not produce the TSC2 gene product, tuberin. TSC2-/- ASM cell proliferation is EGF-dependent.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 138 141 138 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 329 332 329 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 360 363 360 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 498 501 498 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 592 595 592 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 866 869 866 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1007 1011 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
Effects of EGF on proliferation of TSC2-/- ASM cells and TSC2-/- ASM cells transfected with TSC2 gene were determined. In contrast to TSC2-/- ASM cells, growth of TSC2-transfected cells was not dependent on EGF. Moreover, phosphorylation of Akt, PTEN, Erk and S6 was significantly decreased. EGF is a proliferative factor of TSC2-/- ASM cells. Exposure of TSC2-/- ASM cells to anti-EGFR antibodies significantly inhibited their proliferation, reverted reactivity to HMB45 antibody, a marker of TSC2-/- cell phenotype, and inhibited constitutive phosphorylation of S6 and ERK. Exposure of TSC2-/- ASM cells to rapamycin reduced the proliferation rate, but only when added at plating time. Although rapamycin efficiently inhibited S6 phosphorylation, it was less efficient than anti-EGFR antibody in reverting HMB45 reactivity and blocking ERK phosphorylation. In TSC2-/- ASM cells specific PI3K inhibitors (e.g. LY294002, wortmannin) and Akt1 siRNA had little effect on S6 and ERK phosphorylation. Following TSC2-gene transfection, Akt inhibitor sensitivity was observed.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 123 126 123 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Our results show that an EGF independent pathway is more important than that involving IGF-I for growth and survival of TSC-/- ASM cells, and such EGF-dependency is the result of the lack of tuberin.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Young1">[1]</xref>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC1</italic>
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 319 322 319 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Janssen1">[2]</xref>
###xml 324 327 324 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-European1">[3]</xref>
###xml 426 429 426 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Gomez1">[4]</xref>
###xml 435 439 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC1</italic>
###xml 555 559 555 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 565 568 565 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Young1">[1]</xref>
###xml 700 703 700 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Kenerson1">[5]</xref>
###xml 705 708 705 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-vanSlegtenhorst1">[6]</xref>
###xml 1003 1006 1003 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Goncharova1">[7]</xref>
###xml 1035 1038 1035 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Kwiatkowski1">[8]</xref>
###xml 995 1002 <span type="species:ncbi:9606">patient</span>
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the development of hamartomas, which are unusual tumor-like growths found in a variety of tissues [1]. The two genes implicated in tuberous sclerosis, TSC1 and TSC2, with loci on chromosomes 9q34 (TSC1) and 16p13.3 (TSC2) respectively [2], [3], participate in the control of cell size via the insulin/p70 ribosomal S6 kinase 1 (S6K1) pathway [4]. The TSC1 gene codes for hamartin, a 130-kDa hydrophilic protein with no homology to tuberin, the 200-kDa protein encoded by TSC2 gene [1]. Tuberin and hamartin function together as a heterodimer to inhibit mammalian target of rapamycin (mTOR)-mediated signaling to S6K [5], [6]. This complex acts downstream of PI3K and Akt, and upstream of Rheb, mTOR and p70S6K1. In mammalian cells, Rheb overexpression greatly enhances mTOR signaling. The lack of tuberin or hamartin promotes p70S6K activation and S6 phosphorylation, and increased DNA synthesis in cultures of patient [7], and established cell lines [8].
###end p 9
###begin p 10
###xml 195 198 195 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Gingras1">[9]</xref>
###xml 200 204 200 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Takata1">[10]</xref>
###xml 395 404 395 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(p44mapk)</sup>
###xml 415 424 415 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(p42mapk)</sup>
###xml 701 705 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Karbowniczek1">[11]</xref>
###xml 707 711 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Roux1">[12]</xref>
###xml 713 717 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Ma1">[13]</xref>
###xml 811 815 811 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Roux1">[12]</xref>
###xml 1016 1020 1016 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Han1">[14]</xref>
Insulin and other growth factors are thought to regulate the phosphorylation of S6K1 and 4E-binding protein 1 (4EBP1) through the PI3K-signaling pathway via phosphorylation and activation of Akt [9], [10]. Tuberin regulates and is, itself, regulated by p42/44 mitogen-activated protein kinase (MAPK). Activation of the MAPK pathway by growth factors leads to phosphorylation of two MAPKs, Erk-1 (p44mapk) and Erk-2 (p42mapk), which translocate to the nucleus to regulate gene transcription. The tuberin-dependent phosphorylation of B-raf and p42/44 MAPK, the p42/44 MAPK-dependent direct phosphorylation of tuberin and that mediated through S6K suggest an interaction between MAPK pathway and tuberin [11], [12], [13]. Ras/MAPK and PI3K pathways converge on the tumor suppressor tuberin to inhibit its function [12]. MAPK-dependent phosphorylation of tuberin may lead to somatic inactivation of the hamartin/tuberin complex in tuberous sclerosis complex-associated brain hamartomas that have activated MEK1 and ERK1 [14].
###end p 10
###begin p 11
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 767 770 767 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1059 1063 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Carelli1">[16]</xref>
###xml 1186 1190 1186 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 156 163 <span type="species:ncbi:9606">patient</span>
We have isolated and characterized a homogenous population of human smooth muscle like-cells (TSC2-/-ASM cells) from an angiomyolipoma obtained from a TSC2 patient after total nephrectomy. The cells bear a germline TSC2 mutation, consisting of a single base-pair change resulting in replacement of lysine 698 with a stop codon (K698X), as well as loss of heterozygosity (LOH), and do not express tuberin [15]. These cells present the typical constitutive activation of S6K1 and S6, and greater phosphorylation of Akt and ERK, contain melanocyte antigens and react with monoclonal antibody HMB45, which recognizes the gp100 protein. When grown in culture, these cells appear not to undergo senescence based on morphological, biochemical, and pharmacological data. TSC2-/-ASM cells require epidermal growth factor (EGF) in the growth medium for proliferation, and its replacement with IGF-I greatly reduces cell growth. IGF-I, however, is important for these cells. They secrete IGF-I, which may act as a survival factor by promoting the expression of survivin [16]. Blockade of either EGF receptors or IGF-I receptors with specific antibodies resulted in total cell death within 12 days [15].
###end p 11
###begin p 12
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 322 325 322 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 770 773 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 909 912 909 912 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1072 1076 1072 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 312 317 <span type="species:ncbi:9606">human</span>
###xml 760 765 <span type="species:ncbi:9606">human</span>
In the present study, we aimed at evaluating the role of EGF pathway in growth and survival of TSC2-/- ASM cells, and the relationship between the lack of tuberin and the dependency on EGF by these cells. In addition we aimed at understanding the role of PI3K pathway. Here, we show that the EGF requirement for human TSC2-/-ASM cell growth is caused by lack of tuberin. Blockade of the EGF receptor inhibited cell proliferation and S6 and ERK phosphorylation, and caused a rapid reversion of phenotype, as determined by HMB45 reactivity. Rapamycin affected cell growth only when applied at plating time. Through the inhibition of PI3K with specific inhibitors or transient transfection of the cells with siRNA oligomer for Akt1, we show that proliferation of human TSC2-/-ASM cell is not dependent upon the functionality of PI3K pathway. In contrast, ERK plays a key role in the regulation of growth. In TSC2-/- ASM cells the PI3K inhibition, by PI3K inhibitors and siRNA Akt1, was inefficient, while its functionality was re-stablished following transformation with the TSC2 gene.
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
Cell lines
###end title 14
###begin p 15
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 514 516 514 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 626 628 626 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 756 758 748 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 849 853 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Arbiser1">[17]</xref>
###xml 793 799 <span type="species:ncbi:9913">bovine</span>
###xml 864 869 <span type="species:ncbi:9606">human</span>
###xml 983 989 <span type="species:ncbi:9913">bovine</span>
###xml 1190 1196 <span type="species:ncbi:9913">bovine</span>
TSC2-/-ASM cells were isolated, characterized and grown, as previously described [15]. They were obtained from a renal angiomyolipoma during total nephrectomy from a 42-year-old female with a history of TSC2 who had given written informed consent according to the Declaration of Helsinki. The study was approved by the Institutional Review Board of Milan's San Paolo Hospital. The culture medium contained a 50/50 mixture of DMEM/Ham F12 (Euroclone; Paignton; United Kingdom) supplemented with hydrocortisone (2x10-7 M) (Sigma-Aldrich, St. Louis, USA), epidermal growth factor (10 ng/ml) (Sigma-Aldrich), sodium selenite (5x10-8 M) (Sigma-Aldrich), insulin (25 microg/ml) (Sigma-Aldrich), transferrin (10 microg/ml) (Sigma-Aldrich), ferrous sulfate (1.6x10-6 M) (Sigma-Aldrich), and 15% fetal bovine serum (Euroclone) as described by Arbiser et al. [17]. The CT/G human aorta vascular smooth muscle cells (VSMCs) (ATCC, Manassas, USA) were grown with F12 medium containing 10% fetal bovine serum, 100 U/ml penicillin and streptomycin and 2 mM L-glutamine (Euroclone). GP2-293 packaging cells (BD-Biosciences-Clontech, Palo Alto, CA USA) were grown in low-glucose DMEM medium with 10% fetal bovine serum, 100 U/ml each penicillin and streptomycin and 2 mM L-glutamine.
###end p 15
###begin title 16
Generation of tuberin-expressing cell lines
###end title 16
###begin p 17
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Astrinidis1">[18]</xref>
###xml 511 514 499 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 711 715 695 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 705 710 <span type="species:ncbi:9606">human</span>
Transfection was performed as previously described by Astrinidis et al. (2002) [18]. Briefly, GP2-293 cells were co-transfected with 2 microg of the retroviral vector pMSCVneo (a gift from Dr. A. Astrinidis and E.P. Henske, Fox Chase Cancer Center, Philadelphia, PA, USA), 1 microg pVSV-G (BD-Biosciences-Clontech) encoding the viral glycoprotein, and 6 microl FuGene6 (Roche, Indianapolis, IN, USA). Replication-deficient retroviruses were collected from the culture after 72 h and applied to subconfluent TSC2-/-ASM cells in the presence of 8 microg/ml polybrene (Sigma-Aldrich). Cells were transduced with empty pMSCVneo vector as a control, or a pMSCVneo construct containing the coding region of the human TSC2 gene. Stable clones were selected for 2 weeks in the presence of 100 microg/ml G418 (Sigma).
###end p 17
###begin title 18
Evaluation of Cell Proliferation
###end title 18
###begin p 19
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Cellular proliferation was evaluated by counting at least 400-500 cells in a Neubauer chamber. TSC2-/- ASM and transfected-cells were grown with or without EGF (10 ng/ml) or substituting IGF-1 (50 ng/ml) to EGF in the culture medium for 30 days. Cells were counted after 7, 15, 20 and 30 days. Each data point was the mean of three independent experiments.
###end p 19
###begin p 20
###xml 186 189 182 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
The actions of rapamycin (Rapamune-Sirulimus, Wyeth Europa, UK; 1 ng/ml) and anti-EGFR (clone 225; 5 microg/ml; Calbiochem, Darmstadt, Germany) were evaluated by adding the drugs to TSC2-/- ASM cells at plating time or 3 hours after plating for 12 days. The effect of different doses of rapamycin (5, 10, and 20 ng/ml) was evaluated by adding rapamycin 3 hours after plating for 12 days. Cells were counted after 2, 5, 7, 10, 12 days. Each data point was the mean of three independent experiments.
###end p 20
###begin title 21
Immunofluorescence Microscopy
###end title 21
###begin p 22
###xml 415 421 <span type="species:ncbi:9986">rabbit</span>
###xml 427 432 <span type="species:ncbi:10090">mouse</span>
###xml 524 528 <span type="species:ncbi:9925">goat</span>
###xml 534 540 <span type="species:ncbi:9986">rabbit</span>
Cells were cultured on glass slides, then permeabilized with 70% methanol for 10 min, and dried in air. The primary antibodies against alpha-actin (1:100; Sigma), HMB45 (1:100; Dako, Carpinteria, CA USA), and tuberin (C-20) (1:100; Santa Cruz, Santa Cruz, CA, USA) were applied overnight at 4degreesC. The samples were incubated for three hours at room temperature with fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse antibody (Chemicon, Temecula, CA, USA) for HMB45, and alpha-actin and rhodamine-conjugated goat anti-rabbit antibody (Chemicon) for studies with tuberin. After washing, the slides were mounted in FluorSave reagent (Calbiochem, Darmstadt, Germany).
###end p 22
###begin p 23
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 853 854 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
HMB45 reactivity was evaluated by immunofluorescence. TSC2-/- ASM cells were incubated for 48 hours or 5 days. Rapamycin (1 ng/ml) or anti-EGFR (5 microg/ml) was added at plating time or 3 hours after plating. HMB45 labeling was defined as strong (++), intermediate (+) and negative (-). HMB45 reactivity was evaluated also after TSC2-transfection. Quantification of HMB45 intensity was achieved with a confocal microscope (Leica TCS-SP2) and analyzed by Leica Confocal software using the profile through stack/series methods as follows: 30 equal polygonal areas covering the cells were randomly selected for each image. The fluorescence intensity values of the selected cells were quantified and the mean and the standard deviation of the data were calculated by the GraphPad software. The level of statistical significance was determined by Student's t-test.
###end p 23
###begin title 24
Cell treatment
###end title 24
###begin p 25
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
For evaluating the effects of anti-EGFR and rapamycin on TSC2-/- ASM cells rapamycin (1 ng/ml) or anti-EGFR antibody (5 microg/ml) were added to the culture medium at plating time or 3 hours after plating for 24 or 48 hours.
###end p 25
###begin p 26
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
For PI3K pathway evaluation , TSC2-/- ASM and transfected cells were incubated for 2 hours with IGF-I (50 ng/ml) with or without LY294002 (20 microM), PD98059 (30 microM), or wortmannin (80 nm or 320 nM). The experiments were performed in complete medium or after 24 hours starvation.
###end p 26
###begin title 27
Western blotting
###end title 27
###begin p 28
Cells were lysed in lysis buffer (5 mM EDTA, 100 mM deoxycholic acid, 3% SDS). Samples (50 microg per lane) were boiled for 5 min, and analyzed by 10% SDS-PAGE. After transfer to nitrocellulose membranes (Amersham, Arlington Height, USA) and blocking at room temperature for 3 h with 5% dry milk (Merck, Darmstadt, Germany), membranes were incubated overnight at 4degreesC with antibodies against tuberin (C-20) (1:100; Santa Cruz), phospho-Akt (1:1000; Cell Signaling; Beverly, CA, USA), Akt (1:200; Santa Cruz), phospho-S6K (1:1000; Cell Signaling), S6K1 (1:1000; Cell Signaling), phospho-S6 (1:1000; Cell Signaling), S6 (1:1000; Cell Signaling), phospho-extracellular signal-regulated kinase 1 and 2 (ERK1/2) (1:1000; Cell Signaling), EGF receptor (Cell Signaling), IGF-I receptor (1:1000; Cell Signaling), phospho-PTEN (Cell Signaling), PTEN (1:1000; Cell Signaling) or beta-actin (Cell Signaling). Membranes were washed, then incubated for 1 hour with the appropriate secondary antibodies (1:10000; Chemicon). The reaction was quantified using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA). Densitometric analysis was performed by Kodak MJ project program. Data were expressed as optical density.
###end p 28
###begin title 29
siRNA transfection
###end title 29
###begin p 30
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
TSC2-/-ASM or TSC2-transformed cells were transfected with small interfering RNA (siRNA) to reduce Akt isoforms. Custom-made validated siRNAs for Akt1 isoforms were obtained from Ambion (Austin, USA). The siRNA duplexes (50 nM) were introduced with Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, USA) per manufacturer's protocol. The cells were assayed after 72 hours.
###end p 30
###begin title 31
Statistical Analysis
###end title 31
###begin p 32
###xml 94 95 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 132 133 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
All data are expressed as means values+/-SEM, and were statistically analyzed using Student's t-test; significance is indicated for P values of *<0.005, **<0.01 and ***<0.001.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
###xml 70 73 70 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 60 65 <span type="species:ncbi:9606">human</span>
Development of cells with stable expression of tuberin from human TSC2-/-ASM cells
###end title 34
###begin p 35
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 235 238 235 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 300 314 300 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g001">Fig. 1A and 1B</xref>
###xml 580 587 580 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g001">Fig. 1B</xref>
###xml 640 643 640 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 673 677 673 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 692 699 692 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g001">Fig. 1C</xref>
###xml 886 889 886 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 899 903 899 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 920 924 920 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 968 975 968 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g001">Fig. 1C</xref>
###xml 1031 1035 1031 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 1196 1200 1196 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Bagby1">[19]</xref>
###xml 1206 1209 1206 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1217 1221 1217 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 1380 1384 1380 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 1404 1411 1404 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g001">Fig. 1C</xref>
###xml 1474 1478 1474 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 187 192 <span type="species:ncbi:9606">human</span>
###xml 398 403 <span type="species:ncbi:9606">human</span>
###xml 876 881 <span type="species:ncbi:9606">human</span>
###xml 1448 1453 <span type="species:ncbi:9606">human</span>
TSC2-/- ASM cell proliferation required EGF in the culture medium [15]. To study the correlation between the proliferative role of EGF and tuberin in ASM cells, the full-length wild-type human tuberin was successfully expressed in TSC2-/-ASM cells following retroviral transduction of the TSC2 gene (Fig. 1A and 1B). Expression and cellular distribution of tuberin was comparable to that of normal human vascular smooth muscle cells (VSMCs) and has been observed for up to 4 months. It was localized primarily in the cell body and to a smaller extent in the peripheral processes (Fig. 1B). The expression of EGF- and IGF-I-receptors in TSC2-/-ASM cells was not affected by TSC2 transfection (Fig. 1C); however, the responses to these factors were significantly different in transfected and non-transfected cells. Addition of EGF to the growth medium promotes proliferation of human TSC2-/-ASM cells [15], but, following TSC2 transfection, EGF inhibited proliferation (Fig. 1C). This action of EGF was reported previously for VSMCs [15] and apparently results from EGF-dependent early DNA synthesis, accompanied by minimal cell division for 0 to 4 days, that leads to subsequent cell cycle arrest [19]. TSC2-/-ASM and TSC2-transfected cells grew at a comparable rate in the medium lacking EGF. The addition of IGF-I to the growth medium slightly improved the proliferation rate of TSC2-transfected cells (Fig. 1C), as reported previously for normal human smooth muscle cells [15].
###end p 35
###begin title 36
###xml 87 90 87 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
Development of smooth muscle cells with stable human tuberin expression from human TSC2-/-ASM cells.
###end title 36
###begin p 37
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 262 265 262 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 475 478 475 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 534 537 534 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 585 588 585 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 611 615 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 1044 1045 1042 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 878 883 <span type="species:ncbi:9606">human</span>
A: Expression of tuberin was evaluated by Western blotting in TSC2-/-ASM cells, TSC2-transfected cells (transf. cells), and AML. The slight expression in AML is due to the presence of non-LOH TSC2 cells. B: Tuberin was undetectable by immunocytochemistry in TSC2-/-ASM cells, but it was expressed in these cells following TSC2 transfection. Aorta smooth muscle cells (VSMC) show immunolabeling of tuberin. C: Evaluation of EGF effects following TSC2-gene transfection in TSC2-/-ASM cells. Insert: EGFR and IGF-IR are expressed in TSC2-/-ASM cells, TSC2-transfected cells, and AML. TSC2-/-ASM cells require, and TSC2-transfected cells (tTSC2 cells) do not require, EGF in the medium for cell proliferation. IGF-I promotes proliferation of TSC2-transfected cells and normal smooth muscle cells. EGF has a negative effect on proliferation of transfected cells as it does on normal human smooth muscle cells. Experiments were done three times each. Mean values+/-SEM. Significant differences (***P<0.001) versus control were evaluated by student's t-test.
###end p 37
###begin p 38
###xml 104 107 104 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Kenerson1">[5]</xref>
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Goncharova1">[7]</xref>
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Inoki1">[20]</xref>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Karbowniczek2">[21]</xref>
###xml 228 231 228 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 301 308 301 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g002">Fig. 2A</xref>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 393 396 393 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 541 548 541 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g002">Fig. 2A</xref>
###xml 624 628 624 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 722 729 722 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g002">Fig. 2B</xref>
Enhanced phosphorylations of Akt, S6K1 and S6 can be considered a biochemical marker of TSC2 deficiency [5], [7], [15], [20], [21]. The extent of Akt, S6K1 and S6 phosphorylation was reduced in transformed cells compared to TSC2-/-ASM cells, while the expression of Akt and S6 proteins was unaltered (Fig. 2A). PTEN phosphorylation was markedly lower in TSC2-transfected cells compared to TSC2-/- ASM cells, and this was similar to what was observed with Akt. As expected, the extent of ERK phosphorylation was reduced by TSC2-transfection (Fig. 2A). Thus, reduced Akt, PTEN, ERK, and S6 phosphorylation was associated with TSC2 transfection as evidenced by the reduced ratios of phosphorylated to specific protein level (Fig. 2B).
###end p 38
###begin title 39
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
Biochemical rearrangements promoted by TSC2 transfection.
###end title 39
###begin p 40
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
A: Constitutive phosphorylation of Akt, PTEN, S6K1, and S6 was markedly decreased by TSC transfection; interestingly also the extent of ERK phosphorylation was reduced. B: Also the phosphorylated form to total protein ratio shows a marked reduction of the extent of phosphorylation caused by TSC2-gene transfection. The blots are representative of three separate experiments.
###end p 40
###begin title 41
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Effect of anti-EGFR antibody and rapamycin on TSC2-/-ASM cell growth and phenotype
###end title 41
###begin p 42
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 526 529 522 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 608 615 604 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g003">Fig. 3A</xref>
###xml 744 747 740 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 837 844 833 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g003">Fig. 3B</xref>
###xml 933 936 929 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1063 1067 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 1261 1264 1257 1260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1276 1285 1272 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003558.s001">Figure S1</xref>
###xml 87 92 <span type="species:ncbi:9606">human</span>
From observations reported above, it appears that EGFR is involved in proliferation of human TSC2-/- ASM cells. Inhibitory effects of anti-EGFR antibody and rapamycin on proliferation were observed by adding them to the culture medium prior or after cell attachment to the dish. We chose the different timing of application because cells may change the sensitivity to drugs following adhesion. The addition of anti-EGFR antibody (5 microg/ml) either at plating time or 3 hours after plating, led to an early inhibition of TSC2-/-ASM cell proliferation, followed by almost complete cell death within 12 days (Fig. 3A). In contrast, the addition of rapamycin (1 ng/ml) (at plating time), which inhibits mTOR, slowed the proliferation rate of TSC2-/-ASM cells, while a delay of 3 hours eliminated the effects of rapamycin on proliferation (Fig. 3B). The 1 ng/ml concentration of rapamycin was used because it was able to reduce the TSC2-/- ASM cell growth rate to levels similar to controls in presence or absence of EGF in the growth media as shown in Lesma et al. [15]. We have also employed higher concentrations (up to 20 ng/ml) of rapamycin, and only the highest concentrations of 10 and 20 ng/ml were able to slightly reduce the proliferation ability of TSC2-/- ASM cells (Figure S1). All these concentrations, similarly, to 1 ng/ml were capable of blocking the constitutive phosphorylation of S6 (data not shown).
###end p 42
###begin title 43
###xml 57 60 57 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Effect of anti-EGFR antibody and rapamycin (rapa) on TSC2-/-ASM cell growth.
###end title 43
###begin p 44
###xml 157 160 153 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 256 259 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 460 461 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
A: 72 hour incubation: anti-EGFR antibody incubation (5 microg/ml) at plating time and 3 hours after plating inhibited proliferation and caused a marked TSC2-/-ASM cell death. B: Incubation at plating time with rapamycin (1 ng/ml) slowed significantly TSC2-/-ASM cell growth, while its addition at 3 hours after plating failed to affect proliferation. Mean values+/-SEM. Significant differences (*P<0.05, ***P<0.001) versus control were evaluated by student's t-test.
###end p 44
###begin p 45
###xml 142 149 142 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g004">Fig. 4A</xref>
###xml 401 408 401 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g004">Fig. 4B</xref>
###xml 436 439 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 477 486 477 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g004">Figure 4A</xref>
###xml 539 546 539 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g004">Fig. 4A</xref>
Exposure, at plating time, to rapamycin (1 ng/ml) and anti-EGFR antibody greatly reduced S6 and ERK constitutive phosphorylation at 48 hours (Fig. 4A). A delay of 3 hours in drug addition however, revealed different responses of the two reagents. Anti-EGFR antibody reduced both S6 and ERK phosphorylation in 48 hours, while rapamycin reduced S6 phosphorylation but no longer affected ERK activation (Fig. 4B). S6 phosphorylation inTSC2-/- ASM cells was not affected by IGF-I (Figure 4A), while ERK phosphorylation was slightly increased (Fig. 4A).
###end p 45
###begin title 46
Effect of rapamycin (rapa) (1 ng/ml) and anti-EGFR (5 microg/ml) and IGF-I (50 ng/ml) on phosphorylation of S6 and ERK.
###end title 46
###begin p 47
The blots are representative of three experiments. A: Incubation with rapamycin at plating time for 24 or 48 hours inhibited S6 phosphorylation even in the presence of IGF-I. Also anti-EGFR antibody affected the extent of S6 phosphorylation at 48 hours. ERK phosphorylation is reduced by both agents after 48 hours. B: When the drugs are added 3 hours after cell plating, rapamycin reduces S6 phosphorylation in 24 and 48 hours incubation but failed to affect ERK phosphorylation. Anti-EGFR antibody inhibited both S6 and ERK phosphorylation within 48 hours. IGF-I alone did not affect the extent of S6 and ERK phosphorylation.
###end p 47
###begin p 48
###xml 96 99 96 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 230 233 230 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-ElHashemite1">[22]</xref>
###xml 429 432 429 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 522 529 522 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g005">Fig. 5A</xref>
###xml 708 715 708 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g005">Fig. 5A</xref>
###xml 871 878 871 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g005">Fig. 5A</xref>
###xml 984 987 984 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1088 1095 1088 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g005">Fig. 5B</xref>
###xml 1249 1256 1249 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g005">Fig. 5C</xref>
###xml 1324 1331 1324 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g005">Fig. 5D</xref>
###xml 1364 1368 1364 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 1397 1400 1397 1400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1521 1534 1521 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g005">Fig. 5E and F</xref>
###xml 1676 1679 1676 1679 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
To correlate the effects of rapamycin and anti-EGFR antibody on proliferation to changes in TSC2-/-ASM cell phenotype, gp100 expression, quantified with HMB45 antibody, was examined after 48 hours and 5 days of drug exposure. TSC2-/-ASM cells are reactive with HMB45 antibody, a marker of TSC and LAM cells [15], [22]. HMB45 reactivity was quantified as strong (++), intermediate (+) and negative (-). About 80% of untreated TSC2-/-ASM cells were strongly reactive with HMB45, 13% slightly labelled, and 6% were negative (Fig. 5A). In contrast, after a 48 hour incubation with anti-EGFR antibody added at plating time, 25% of the cells were positive, 32% had an intermediate labelling and 43% were negative (Fig. 5A). A 48 hour incubation with rapamycin, added at plating time, reduced HMB45-reactive cells to 59%, while 19% were negative and 22% were slightly labelled (Fig. 5A). After 5 days of exposure to rapamycin or anti-EGFR antibody added at plating time, 49% and 71%, of TSC2-/- ASM cells, respectively, were not reactive with HMB45; anti-EGFR antibody was still more effective (Fig. 5B). When anti-EGFR antibody or rapamycin was added to the medium 3 hours after plating the reversion of HMB45 reactivity was less marked at earlier times (Fig. 5C), but after a 5 day incubation, both agents suppressed reactivity (Fig. 5D). Following transformation with TSC2 gene, the percentage of TSC2-/- ASM cells negative for the immunoblotting of gp100 protein was greater than 80%, while actin expression was unaffected (Fig. 5E and F). The observed differential sensitivity to the effects of delayed addition of rapamycin on proliferation and gp100 protein expression in TSC2-/-ASM cells suggests that these molecular phenotypes may be regulated differently by TORC and EGFR.
###end p 48
###begin title 49
###xml 116 119 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 106 111 <span type="species:ncbi:9606">human</span>
Effect of rapamycin (1 ng/ml) and anti-EGFR antibody (5 microg/ml) on reactivity with monoclonal HMB45 in human TSC2-/-ASM cells.
###end title 49
###begin p 50
###xml 625 628 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 786 789 786 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 823 826 823 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 842 846 842 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 931 934 927 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 942 946 938 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 1084 1085 1078 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Positive cells are indicated as ++, slightly positive as + and negative as -. A: Incubation at cell plating time with anti-EGFR for 48 hours decreases markedly the number of cells reacting to HMB45 while the number of negative cells is strongly increased. Rapamycin is markedly less than anti-EGFR antibody. B: Incubation for 5 days with either rapamycin or anti-EGFR antibody, applied at cell plating time, caused a significant reduction of HMB45 reactivity in both cases. C: 48 hours exposure to rapamycin or anti-EGFR antibody, both applied 3 hours after plating, caused only a slight reduction of HMB45 reactivity of TSC2-/-ASM cells. D: Exposure to rapamycin or anti-EGFR antibody applied 3 hours after cell plating for 5 days caused a drastic reduction in HMB45 reactivity of TSC2-/-ASM cells. E: Transfection of TSC2-/- ASM cells with TSC2 gene significantly reduced HMB45 reactivity. F: alpha-actin was present in both TSC2-/-ASM and TSC2-transfected cells. Mean values+/-SEM. Significant differences (*P<0.05, **P<0.01, ***P<0.001) versus control were evaluated by student's t-test.
###end p 50
###begin title 51
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
Role of PI3K pathway in TSC2-/- ASM cells
###end title 51
###begin p 52
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Kuemmerle1">[23]</xref>
###xml 269 272 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 384 391 384 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6A</xref>
###xml 546 559 542 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6A and C</xref>
###xml 693 702 689 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003558.s002">Figure S2</xref>
###xml 941 954 929 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6A and C</xref>
###xml 1118 1119 1106 1107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1158 1162 1146 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Powis1">[24]</xref>
###xml 1164 1168 1152 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Cross1">[25]</xref>
Binding of IGF-I to its receptor stimulates the intrinsic tyrosine kinase activity of the receptor, leading to phosphorylation of several substrates that activate downstream intracellular signaling through the PI-3K or Grb2-SOS, ERK1/2 pathways [23]. Incubation of TSC2-/- ASM cells with IGF-I (50 ng/ml) for 2 hours, led to activation of PI3-K, and phosphorylation of Akt on Ser473 (Fig. 6A). LY294002, a cell-permeable PI-3K inhibitor, at 20 microM, slightly inhibited IGF-I-mediated Akt activation without affecting basal Akt phosphorylation (Fig. 6A and C). The lack of effects of LY294002 and PD98059 on Akt phosphorylation was confirmed by the densitometric analysis from 3 experiments (Figure S2). Higher concentrations of LY294002 (100 microM) were no more effective than 20 microM (data not shown). The extent of S6 and S6K1 phosphorylation was unaffected by treatment with IGF-I, and LY294002 or PD98059, a specific ERK inhibitor (Fig. 6A and C). The PI-3K inhibitor, wortmannin, a fungal metabolite, which irreversibly binds mammalian PI-3K and inhibits phosphorylation of several other substrates (e.g. PLA2, PLD, myosin chain kinase, plekstrin) [24], [25] at 80 nM and 320 nM, in presence or absence of IGF-I, did not affect Akt phosphorylation or expression (data not shown).
###end p 52
###begin title 53
###xml 42 45 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
Phosphorylation of Akt, SK1 and S6 in TSC2-/-ASM cells and following TSC2 transfection.
###end title 53
###begin p 54
###xml 21 24 21 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 374 378 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 864 867 856 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 885 888 877 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1090 1094 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
A: Incubation of TSC2-/-ASM cells for 2 hours with IGF-I (50 ng/ml) induced Akt phosphorylation but did not affect S6K1 and S6 phosphorylation. Incubation with PI3K inhibitor, LY294002 (LY; 20 microM), or ERK inhibitor, PD98059 (PD; 30 microM), did not influence the activation of Akt, S6K1 and S6. Expression of Akt, and S6K1 was not altered by any treatment. B: Following TSC2 transfection, LY290042 antagonized IGF-I-mediated and basal phosphorylation of Akt, S6K1, and S6. Expression of Akt, and S6K1 proteins were unaltered. C: Following 24 hours of starvation, phosphorylation of S6K1 and S6, and expression of Akt and S6K1 proteins were unaltered by 2 hour incubation with IGF-I in presence or absence of LY290042 or PD98059. Increased phosphorylation of Akt caused by IGF-I, was unaffected by incubation with LY290042 or PD98059. D: PTEN regulation in TSC2-/-ASM cells. In TSC2-/-ASM cells, phosphorylation of PTEN was increased by incubation for 2 hours with IGF-I (50 ng/ml), and this was not inhibited by LY290042 (20 microM) as observed above for Akt phosphorylation. Following TSC2 transfection, LY290042 effectively inhibited basal and IGF-I promoted phosphorylation of PTEN as described above for Akt.
###end p 54
###begin p 55
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 122 129 122 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6B</xref>
###xml 227 234 223 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6B</xref>
###xml 408 415 404 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6B</xref>
In contrast to these findings, IGF-I-promoted Akt phosphorylation was fully LY294002-sensitive in TSC2-transformed cells (Fig. 6B). LY294002 (20 microM) reduced both basal and IGF-I-induced phosphorylation of Akt, S6 and S6K1 (Fig. 6B). Similar to the findings with Akt, the basal and IGF-I-induced increase of S6 and S6K1 phosphorylation was also markedly reduced by LY294002 addition to transfected cells (Fig. 6B).
###end p 55
###begin p 56
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Perugini1">[26]</xref>
###xml 346 369 338 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6A, data not shown</xref>
###xml 375 379 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 566 576 558 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6A, B</xref>
###xml 711 714 703 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 726 733 718 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6C</xref>
###xml 743 746 735 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 751 755 743 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 865 878 857 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6A and B</xref>
To evaluate the role of ERK1/2, TSC2-/- ASM cells were incubated with IGF-I and PD98059, which blocks MEK1 activity and thus ERK phosphorylation and activation [26]. When 30 microM or 90 microM PD98059 was added for 2 hours to the culture medium in the presence or absence of IGF-I, no effect was observed on phosphorylation of Akt, S6 and S6K1 (Fig. 6A, data not shown). In TSC2-transfected cells, PD98059 did not affect Akt phosphorylation, but IGF-I-induced phosphorylation of S6 and S6K1 was blocked. Expression of Akt and S6K1 was not altered by any treatment (Fig. 6A, B). Following serum deprivation for 24 hours, LY294002 or PD98059 failed to affect Akt, S6K and S6 phosphorylation in IGF-I-treated TSC2-/- ASM cells (Fig. 6C). In TSC2-/- and TSC2-transfected ASM cells ERK phosphorylation was slightly increased by IGF-I exposure and inhibited by PD98059 (Fig. 6A and B).
###end p 56
###begin p 57
###xml 176 177 176 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 234 235 234 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Stambolic1">[27]</xref>
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 339 340 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 389 393 389 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Zhang1">[28]</xref>
###xml 470 473 470 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 518 525 518 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6D</xref>
###xml 567 571 567 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 652 659 652 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g006">Fig. 6D</xref>
PTEN phosphatase acts as a negative regulator of the PI-3K signaling pathway by dephosphorylating the second messengers phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P3] and phosphatidylinositol-3,4-bisphosphate [PtdIns(3,4)P2], thereby opposing PI-3K function [27]. It has been proposed that greater Akt phosphorylation in TSC2-/- cells might be related to reduced PTEN activity [28]. A 2 hour exposure to IGF-I (50 ng/ml) enhanced PTEN phosphorylation in TSC2-/-ASM cells in an LY294002-insensitive manner (Fig. 6D). Following transformation of cells with TSC2, LY294002 effectively blocked basal and IGF-I-promoted phosphorylation of PTEN (Fig. 6D). These data suggest that the extent of PTEN phosphorylation changes in parallel with Akt activity. Higher levels of Akt phosphorylation were associated with greater PTEN phosphorylation and vice versa.
###end p 57
###begin p 58
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 166 172 166 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g007">Fig. 7</xref>
###xml 293 296 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 385 392 385 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g007">Fig. 7A</xref>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 511 514 511 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 595 602 595 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g007">Fig. 7B</xref>
To study further the role of AKT in TSC2-/- ASM cells, endogenous Akt1 gene expression was inhibited by transient transfection with Akt siRNA in the presence of EGF (Fig. 7). Akt1 siRNA reduced both Akt protein expression and phosphorylation, indicating a greater preponderance of Akt1 in TSC2-/-ASM cells. Phosphorylation and expression of S6 and ERK were not affected by Akt1 siRNA (Fig. 7A). The siRNA in TSC2 transfected cells caused the drop of both Akt and phospho-Akt levels that, differently that in TSC-/- ASM cells, is accompanied by the reduction in the extent of S6 phosphorylation (Fig. 7B). Such effect was also observed in normal vascular smooth muscle cells VSMCs (data not shown).
###end p 58
###begin title 59
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
Transient transfection with siRNA for Akt1 in TSC2-/-ASM and TSC2-transfected cells.
###end title 59
###begin p 60
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 168 172 168 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
A: In TSC2-/-ASM cells siRNA for Akt1 drastically inhibited Akt expression and phosphorylation, but it did not affect PTEN, S6 and ERK expression and activation. B: In TSC2-transfected cells siRNA for Akt1 inhibited the level and the phosphorylation of Akt and S6 phosphorylation.
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 48 51 48 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 101 105 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 93 100 <span type="species:ncbi:9606">patient</span>
We had previously reported the isolation of TSC2-/-ASM cells from an angiomyolipoma of a TSC patient [15]. These cells have been grown for the past 4 years, and the original morphological, genetic and biochemical characteristics, such as reactivity to anti-alpha-actin and HMB45 antibodies, and EGF-dependent growth, were fully maintained.
###end p 62
###begin p 63
###xml 320 321 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Carelli1">[16]</xref>
###xml 521 524 521 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 731 734 731 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 926 930 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 932 936 932 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Kuemmerle2">[29]</xref>
###xml 938 942 938 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 999 1002 999 1002 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 989 994 <span type="species:ncbi:9606">human</span>
Deregulation of the pathways that control cell proliferation and survival, such as those regulated by Ras/MAPK and PI3K, is a major characteristic of abnormal tumor growth and following mutations of tumor-suppressor genes leads to the formation of benign, rather than malignant, tumors. The rate of proliferation of TSC2-/- ASM cells is sensitive to the addition of EGF to the growth medium, while secretion of IGF-I is involved in survival [15], [16]. Here, we report that the viral-induced expression of tuberin in TSC2-/- ASM cells greatly reduced the growth rate, EGF ceased to be a required growth factor, and instead, it inhibited proliferation. These results support the original hypothesis that the EGF requirement for TSC2-/-ASM cell proliferation is dependent upon the lack of tuberin. Similar to what it is observed in normal smooth muscle cells, IGF-I slightly enhanced the proliferation rate of transfected cells [15], [29]. TSC2-transfection reversed the typical features of human TSC2-/-ASM cells, i.e. the abnormal EGF-dependent proliferation, constitutive S6 phosphorylation, and reactivity with HMB45 without affecting the smooth muscle phenotype.
###end p 63
###begin p 64
###xml 37 41 37 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lesma1">[15]</xref>
###xml 121 124 121 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Vokes1">[30]</xref>
###xml 563 567 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Vokes1">[30]</xref>
###xml 787 791 787 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Vokes1">[30]</xref>
###xml 908 912 908 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Harwood1">[31]</xref>
###xml 1035 1039 1035 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 1039 1042 1039 1042 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1048 1052 1048 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Kenerson2">[32]</xref>
###xml 1054 1058 1054 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Lee1">[33]</xref>
###xml 1383 1387 1383 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Bissler1">[34]</xref>
###xml 1500 1501 1500 1501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1502 1503 1502 1503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1714 1717 1714 1717 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1959 1962 1959 1962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2179 2183 2179 2183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 1018 1021 <span type="species:ncbi:10116">rat</span>
###xml 1043 1047 <span type="species:ncbi:10090">mice</span>
###xml 1265 1273 <span type="species:ncbi:9606">patients</span>
###xml 1704 1709 <span type="species:ncbi:9606">human</span>
Further extending the previous study [15], we evaluated the action of anti-EGFR antibody and rapamycin in regulating TSC2-/- ASM cell growth. EGFR is an important target of anticancer therapy. The EGFR signalling pathways regulate cell differentiation, proliferation, migration, angiogenesis and apoptosis, all of which become deregulated in cancer cells [30]. One current strategy to block cancer growth involves the use of antibodies against the extracellular domain of EGFR, which compete with ligand for receptor binding, thereby preventing kinase activation [30]. As an example, the antibody used in this study, monoclonal antibody C225, has a high affinity for EGFR and has been shown to be efficacious in several types of cancer, particularly colorectal and head and neck cancers [30]. Rapamycin specifically inhibits mTOR, while anti-EGFR blocks a complex pathway that involves ERK, RSK1 and tuberin [31]. Rapamycin has been shown to induce apoptosis, decrease proliferation, and reduce tumor size in the Eker rat model and in TSC2+/- mice [32], [33]. Since mTOR is directly activated upon loss of hamartin or tuberin, rapamycin has been identified as a potential therapeutic agent for TSC and LAM. It has been recently reported that angiomyolipomas of TSC patients regressed partially during rapamycin treatment, but the volume increased again after the therapy was stopped [34]. Our data indicate that anti-EGFR antibody has a greater ability than rapamycin to inhibit proliferation of TSC2-/- ASM cells, counteract the phosphorylation of S6 and ERK, and reduce HMB45 reactivity. Furthermore, the anti-EGFR antibody-dependent reduction of the proliferation rate led to the progressive death of human TSC2-/-ASM cell when added to the medium either at plating time or 3 hours after plating. In contrast, rapamycin reduced significantly cell proliferation only when added prior cell attachment. The delayed application of rapamycin did not affect TSC2-/- ASM cell proliferation although S6 constitutive phosphorylation is inhibited. This may be explained by the activity of MAPK in these cells. Anti-EGFR antibody and rapamycin, however, were clearly less efficient than TSC2-transfection.
###end p 64
###begin p 65
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 315 318 315 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 566 567 566 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
Consistent with the concept that S6K1 activation is PI3K independent in tuberin-deficient cells, Akt1 siRNA did not interfere with S6 phosphorylation, while PTEN phosphorylation in TSC2-/- and TSC2-transfected cells followed the activation pattern of Akt. Exposure to IGF-I enhanced Akt phosphorylation of both TSC2-/- ASM cells and those virally transfected with TSC2 gene; however, PI3K inhibitors, such as LY294002 and wortmannin, were able to affect this process only in TSC2-transfected cells. Thus, it appears that viral-induced expression of tuberin in TSC2-/- ASM cells modifies cellular function and sensitivity to drugs.
###end p 65
###begin p 66
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Peng1">[35]</xref>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Ma1">[13]</xref>
###xml 484 487 484 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 802 806 802 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Roux1">[12]</xref>
###xml 821 824 821 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1025 1033 1025 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003558-g008">Figure 8</xref>
###xml 1165 1168 1165 1168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1212 1216 1212 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003558-Carelli1">[16]</xref>
###xml 1339 1342 1339 1342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1583 1587 1583 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSC2</italic>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 811 816 <span type="species:ncbi:9606">human</span>
Serum-stimulated phosphorylation of tuberin was observed in embryonic fibroblasts from Akt1/Akt2 double knockout mice, consistent with the hypothesis that another kinase, such as RSK1, phosphorylates tuberin in response to stimuli that activate the Ras/MAPK pathway [35]. Tuberin is a phosphorylation target of Ras-ERK signalling and phosphorylation results in the suppression of its biochemical and biological tumor-suppressive functions [13]. Viral-driven tuberin expression in TSC2-/-ASM cells decreased phosphorylation of p42/44 MAPK. This effect was also observed with anti-EGFR antibody, whereas rapamycin had a similar effect only when added at plating time. The data are consistent with a regulatory mechanism by which the Ras/MAPK and PI3K pathways converge on tuberin to inhibit its function [12]. In human TSC2-/- ASM cells, the lack of tuberin seems to shift the regulation of cell proliferation to the Ras/MAPK pathway while PI3K cascade appears to activate an independent and different cell signalling pathway (Figure 8). This may explain why IGF-I which has a proliferative action in normal smooth muscle cells, fails to promote proliferation in TSC2-/- ASM cells, and activates survival pathways [16]. From our results it may be also inferred a possible modulation of mTOR by the EGF pathway. We may speculate that, in TSC2-/- ASM cells, Akt is highly phosphorylated because its major substrate, tuberin, is absent while the phosphorilative events are particularly active, expecially mTOR-rictor. In this situation Akt is insensitive to PI3K inhibitors but following TSC2 transfection the sensitivity is restored.
###end p 66
###begin title 67
ERK- and PI3K-Akt-dependent cascades regulating mTOR signalling.
###end title 67
###begin p 68
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 483 486 483 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
A: In wild type cells, activation of either pathways result in the phosphorylation of both RSK1 and Akt that, in turn, are capable of phosphorylating tuberin directly. B: In TSC2-/- ASM cells, the loss of tuberin may lead to modification of ERK-RSK1 function with direct/indirect regulation of mTOR and p706K. ERK-RSK1 pathway appears to have a more relevant role while the PI3K cascade, may not be properly regulated. This might explain the EGF requirement for proliferation of TSC2-/- ASM cells.
###end p 68
###begin p 69
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 433 436 433 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 593 594 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 595 596 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 423 428 <span type="species:ncbi:9606">human</span>
In conclusion, re-expression of tuberin caused a more efficient reversion of phenotypic, proliferative and biochemical characteristics of TSC2-/-ASM cells compared to the pharmacological approach. EGF-dependent TSC2-/- ASM proliferation is related to the lack of tuberin. The anti-EGFR antibody was more efficient than rapamycin in reducing reactivity to HMB45, the proliferation rate, and in controlling ERK activation in human TSC2-/-ASM cells. Both rapamycin and anti-EGFR were equally affected in inhibiting S6 activation, while ERK phosphorylation was more sensitive to anti-EGFR. In TSC2-/- ASM cells, the EGF pathway, involving ERK, may play a more relevant role than a PI3K cascade in cell growth.
###end p 69
###begin title 70
Supporting Information
###end title 70
###begin p 71
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 213 216 213 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Effect of rapamycin (rapa) on TSC2-/-ASM cell growth. Rapamycin addition at the concentrations of 5 ng/ml 3 hours after plating did not have any significant effect on cell growth while 10, and 20 ng/ml slowed TSC2-/-ASM proliferation only after 7 days of incubation. Mean values+/-SEM. Significant differences (*P<0.05) versus control were evaluated by student's t-test
###end p 71
###begin p 72
(5.76 MB TIF)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
###xml 56 59 56 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 140 143 140 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Densitometric analysis of phosphorylation of Akt in TSC2-/-ASM cells in complete medium or following 24 hours starvation. Incubation of TSC2-/-ASM cells and following TSC2-transfection for 2 hours with IGF-I (50 ng/ml) induced Akt phosphorylation. Incubation with PI3K inhibitor, LY294002 (LY; 20 microM), or ERK inhibitor, PD98059 (PD; 30 microM), did not influence the activation of Akt. Expression of Akt was not altered by any treatment. Mean values+/-SEM. Significant differences (***P<0.001) versus control were evaluated by student's t-test.
###end p 74
###begin p 75
(7.38 MB TIF)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
The author thanks Dr. Joel Moss for the helpful discussion and critical reading of the manuscript.
###end p 77
###begin title 78
References
###end title 78
###begin article-title 79
The genetic basis of tuberous sclerosis.
###end article-title 79
###begin article-title 80
Refined localization of TSC1 by combined analysis of 9q34 and 16p13 data in 14 tuberous sclerosis families.
###end article-title 80
###begin article-title 81
Identification and characterization of the tuberous sclerosis gene on chromosome 16.
###end article-title 81
###begin article-title 82
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
###end article-title 82
###begin article-title 83
Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.
###end article-title 83
###begin article-title 84
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the Tsc2 tumor suppressor gene in pulmonary lymphangeioleiomyomatosis (LAM).
###end article-title 84
###begin article-title 85
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
El-Hashemite, and Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.
###end article-title 85
###begin article-title 86
eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation.
###end article-title 86
###begin article-title 87
Requirement for Akt (protein kinase B) in insulin-induced activation of glycogen synthase and phosphorylation of 4E-BP1 (PHAS-1).
###end article-title 87
###begin article-title 88
Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.
###end article-title 88
###begin article-title 89
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
###end article-title 89
###begin article-title 90
Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis.
###end article-title 90
###begin article-title 91
Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions.
###end article-title 91
###begin article-title 92
###xml 91 96 <span type="species:ncbi:9606">human</span>
Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: EGF is the required growth factor.
###end article-title 92
###begin article-title 93
Survivin expression in tuberous sclerosis complex cells.
###end article-title 93
###begin article-title 94
The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma.
###end article-title 94
###begin article-title 95
Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration.
###end article-title 95
###begin article-title 96
Proliferative synergy of ANG II and EGF in porcine aortic vascular smooth cells.
###end article-title 96
###begin article-title 97
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
###end article-title 97
###begin article-title 98
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplatic and non-neoplastic vascular structures.
###end article-title 98
###begin article-title 99
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.
###end article-title 99
###begin article-title 100
IGF-I stimulates intestinal muscle cell growth by activating distinct PI 3-kinase and MAP kinase pathways.
###end article-title 100
###begin article-title 101
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
###end article-title 101
###begin article-title 102
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells.
###end article-title 102
###begin article-title 103
Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent.
###end article-title 103
###begin article-title 104
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.
###end article-title 104
###begin article-title 105
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
###end article-title 105
###begin article-title 106
###xml 17 22 <span type="species:ncbi:9606">human</span>
IGF-I stimulates human intestinal smooth muscle cell growth by regulation of G1 phase cell cycle proteins.
###end article-title 106
###begin article-title 107
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
###end article-title 107
###begin article-title 108
mTORC1 signaling can regulate growth factor activation of p44/42 mitogen activated protein kinases through protein phosphatase 2A.
###end article-title 108
###begin article-title 109
###xml 33 36 <span type="species:ncbi:10116">rat</span>
Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
###end article-title 109
###begin article-title 110
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
###end article-title 110
###begin article-title 111
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis.
###end article-title 111
###begin article-title 112
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2.
###end article-title 112
###begin p 113
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 113
###begin p 114
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Supported by grants on Rare Disease, IRCCS from Ministero Superiore della Sanita (AG, EL); by grant from A.S.T. (Italian Tuberous Sclerosis Association) (EL); by grant from A.I.LAM (Italian Lymphangioleiomyomatosis Association) (AG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 114

